PDE5A and cancer: In contemporaneous parallel studies we had discovered that PDE5 inhibitors in an on-target -dependent fashion could enhance the anti-cancer effects of many standard of care chemotherapeutic drugs, but also of multi-kinase inhibitors such as sorafenib and pazopanib [5–9, 12, 13].